Global expert panel issues first consensus roadmap for brentuximab vedotin nerve damage
Brentuximab vedotin has transformed the outlook for patients with CD30-positive lymphomas, but the antibody-drug conjugate carries a neurological price that ...
Brentuximab vedotin has transformed the outlook for patients with CD30-positive lymphomas, but the antibody-drug conjugate carries a neurological price that ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.